Literature DB >> 14701814

The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II.

Ingrid M Verhamme1, Paul E Bock, Craig M Jackson.   

Abstract

Thrombin (T) inactivation by the serpin, heparin cofactor II (HCII), is accelerated by the glycosaminoglycans (GAGs) dermatan sulfate (DS) and heparin (H). Equilibrium binding and thrombin inactivation kinetics at pH 7.8 and ionic strength (I) 0.125 m demonstrated that DS and heparin bound much tighter to thrombin (K(T(DS)) 1-5.8 microm; K(T(H)) 0.02-0.2 microm) than to HCII (K(HCII(DS)) 236-291 microm; K(HCII(H)) 25-35 microm), favoring formation of T.GAG over HCII.GAG complexes as intermediates for T.GAG.HCII complex assembly. At [GAG] << K(HCII(GAG)) the GAG and HCII concentration dependences of the first-order inactivation rate constants (k(app)) were hyperbolic, reflecting saturation of T.GAG complex and formation of the T.GAG.HCII complex from T.GAG and free HCII, respectively. At [GAG] >> K(HCII(GAG)), HCII.GAG complex formation caused a decrease in k(app). The bell-shaped logarithmic GAG dependences fit an obligatory template mechanism in which free HCII binds GAG in the T.GAG complex. DS and heparin bound fluorescently labeled meizothrombin(des-fragment 1) (MzT(-F1)) with K(MzT(-F1)(GAG)) 10 and 20 microm, respectively, demonstrating a binding site outside of exosite II. Exosite II ligands did not attenuate the DS-accelerated thrombin inactivation markedly, but DS displaced thrombin from heparin-Sepharose, suggesting that DS and heparin share a restricted binding site in or nearby exosite II, in addition to binding outside exosite II. Both T.DS and MzT(-F1).DS interactions were saturable at DS concentrations substantially below K(HCII(DS)), consistent with DS bridging T.DS and free HCII. The results suggest that GAG template action facilitates ternary complex formation and accommodates HCII binding to GAG and thrombin exosite I in the ternary complex.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14701814     DOI: 10.1074/jbc.M313962200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.

Authors:  Suryakala Sarilla; Sally Y Habib; Douglas M Tollefsen; David B Friedman; Diana R Arnett; Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2010-07-27       Impact factor: 3.365

2.  Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex.

Authors:  Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2011-12-06       Impact factor: 3.365

3.  Heparin is a major activator of the anticoagulant serpin, protein Z-dependent protease inhibitor.

Authors:  Xin Huang; Alireza R Rezaie; George J Broze; Steven T Olson
Journal:  J Biol Chem       Date:  2011-01-10       Impact factor: 5.157

Review 4.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

5.  Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.

Authors:  Suryakala Sarilla; Sally Y Habib; Dmitri V Kravtsov; Anton Matafonov; David Gailani; Ingrid M Verhamme
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

6.  Understanding Dermatan Sulfate-Heparin Cofactor II Interaction through Virtual Library Screening.

Authors:  Arjun Raghuraman; Philip D Mosier; Umesh R Desai
Journal:  ACS Med Chem Lett       Date:  2010-06-14       Impact factor: 4.345

7.  Contaminated heparin associated with adverse clinical events and activation of the contact system.

Authors:  Takashi Kei Kishimoto; Karthik Viswanathan; Tanmoy Ganguly; Subbiah Elankumaran; Sean Smith; Kevin Pelzer; Jonathan C Lansing; Nammalwar Sriranganathan; Ganlin Zhao; Zoya Galcheva-Gargova; Ali Al-Hakim; Gregory Scott Bailey; Blair Fraser; Sucharita Roy; Thomas Rogers-Cotrone; Lucinda Buhse; Mark Whary; James Fox; Moheb Nasr; Gerald J Dal Pan; Zachary Shriver; Robert S Langer; Ganesh Venkataraman; K Frank Austen; Janet Woodcock; Ram Sasisekharan
Journal:  N Engl J Med       Date:  2008-04-23       Impact factor: 91.245

8.  The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent adduction of antithrombin III.

Authors:  Richard Jacobson; Nicholas Mignemi; Kristie Rose; Lynda O'Rear; Suryakala Sarilla; Heidi E Hamm; Joey V Barnett; Ingrid M Verhamme; Jonathan Schoenecker
Journal:  Thromb Res       Date:  2014-10-05       Impact factor: 3.944

9.  Lytic and mechanical stability of clots composed of fibrin and blood vessel wall components.

Authors:  Z Rottenberger; E Komorowicz; L Szabó; A Bóta; Z Varga; R Machovich; C Longstaff; K Kolev
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

10.  The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.

Authors:  Amanda J Boyle; Leigh Ann Roddick; Varsha Bhakta; Melissa D Lambourne; Murray S Junop; Patricia C Liaw; Jeffrey I Weitz; William P Sheffield
Journal:  BMC Biochem       Date:  2013-03-07       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.